



(51) International Patent Classification:

C07K 16/28 (2006.01) A61K 31/04 (2006.01)

C07K 14/56 (2006.01)

(21) International Application Number:

PCT/US2021/015939

(22) International Filing Date:

29 January 2021 (29.01.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/968,802 31 January 2020 (31.01.2020) US

63/063,015 07 August 2020 (07.08.2020) US

(71) Applicant: AVILAR THERAPEUTICS, INC. [US/US];
200 Berkeley Street, 18th Floor, Boston, MA 02116 (US).

(72) Inventors: SAULNIER, Mark, George; c/o Avilar Therapeutics, Inc., 200 Berkeley Street, 18th Floor, Boston, MA 02116 (US). CHEN, Jesse, Jingyang; c/o Avilar Therapeutics, Inc., 200 Berkeley Street, 18th Floor, Boston, MA 02116 (US). KARRA, Srinivasa; c/o Avilar Therapeutics, Inc., 200 Berkeley Street, 18th Floor, Boston, MA 02116 (US). SPROTT, Kevin, Tyler; c/o Avilar Therapeutics, Inc., 200 Berkeley Street, 18th Floor, Boston, MA 02116 (US). WILES, Jason, Allan; c/o Avilar Therapeutics, Inc.,

200 Berkeley Street, 18th Floor, Boston, MA 02116 (US). RAY, Soumya; c/o Avilar Therapeutics, Inc., 200 Berkeley Street, 18th Floor, Boston, MA 02116 (US).


(74) Agent: BELLOWS, Brent, R.; Knowles Intellectual Property Strategies, LLC, 400 Perimeter Center Terrace, Suite 200, Atlanta, GA 30346 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS

(57) Abstract: Compounds and compositions that have an asialoglycoprotein receptor (ASGPR) binding ligand bound to an extracellular protein binding ligand for the selective degradation of the target extracellular protein *in vivo* to treat disorders mediated by the extracellular protein are described.



[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*